| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
Trachelogenin targets the Wnt/beta-catenin signaling pathway. Its mechanism involves the concentration-dependent modulation of key protein phosphorylations within this pathway. It acts as an HCV entry inhibitor with activity against viral entry.
|
|---|---|
| ln Vitro |
In cell-free assays, Trachelogenin is an HCV entry inhibitor. In cell lines, it significantly affects the phosphorylation of key proteins in the beta-Catenin signaling pathway, including beta-Catenin, c-Myc, and GSK3, in a concentration-dependent manner, which accounts for its antiproliferative effects.
|
| ln Vivo |
Trachelogenin has been shown to have antiviral effects in HCVcc and HCVpp models. Its analgesic and anti-inflammatory activities have also been demonstrated in vivo. Further in vivo studies are needed to fully characterize its pharmacokinetic and therapeutic potential.
|
| Enzyme Assay |
Cell-free binding assays can be performed using purified proteins to assess binding affinity, for example using Isothermal Titration Calorimetry (ITC). For target engagement in signaling pathways, purified GSK3beta can be used in kinase activity assays with a peptide substrate in the presence of varying concentrations of Trachelogenin.
|
| Cell Assay |
Human cancer cell lines, such as SW480 colon adenocarcinoma cells, are seeded and treated with Trachelogenin. The phosphorylation status of key proteins like beta-Catenin, c-Myc, and GSK3 is assessed by Western blot. Cell proliferation is measured by MTT assays to determine IC50 values.
|
| Animal Protocol |
For in vivo activity, specific animal models are required based on the activity being studied. For antiviral studies, a mouse model with HCV infection could be used, with Trachelogenin administered at doses derived from in vitro and PK studies. For its anti-inflammatory effect, a standard carrageenan-induced paw edema model in rats can be used.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data are limited. Trachelogenin has a molecular weight of 388.41. For in vitro use, it is soluble in DMSO (77.68 mg/mL; 199.99 mM). It is typically stored as a powder at -20degC for up to 3 years and in solution at -80degC for up to 1 year.
|
| Toxicity/Toxicokinetics |
Standard safety precautions for research chemicals apply. Avoid inhalation, ingestion, and skin contact. Use personal protective equipment. Further toxicological studies are required for a full safety assessment.
|
| References | |
| Additional Infomation |
Trachelogenin is a lignan. It has been reported to be found in Saussurea involucrata, Trachelogenin jasminoides, and other organisms with relevant data.
Trachelogenin is a research-grade natural product. It is an HCV entry inhibitor with anti-proliferative, anti-inflammatory, and analgesic activities. Purity: 99.87%. Chemical formula: C21H24O7; molecular weight: 388.41. Storage: -20degC. |
| Molecular Formula |
C21H24O7
|
|---|---|
| Molecular Weight |
388.41106
|
| Exact Mass |
388.152
|
| CAS # |
34209-69-3
|
| PubChem CID |
452855
|
| Appearance |
White to off-white solid powder
|
| Density |
1.300±0.06 g/cm3
|
| Melting Point |
144 ºC
|
| LogP |
2.107
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
28
|
| Complexity |
527
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
COC1=C(C=C(C=C1)C[C@H]2COC(=O)[C@@]2(CC3=CC(=C(C=C3)O)OC)O)OC
|
| InChi Key |
YFVZKLQNMNKWSB-BTYIYWSLSA-N
|
| InChi Code |
InChI=1S/C21H24O7/c1-25-17-7-5-13(9-19(17)27-3)8-15-12-28-20(23)21(15,24)11-14-4-6-16(22)18(10-14)26-2/h4-7,9-10,15,22,24H,8,11-12H2,1-3H3/t15-,21-/m0/s1
|
| Chemical Name |
(3S,4S)-4-[(3,4-dimethoxyphenyl)methyl]-3-hydroxy-3-[(4-hydroxy-3-methoxyphenyl)methyl]oxolan-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~257.46 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (6.44 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (6.44 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.44 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5746 mL | 12.8730 mL | 25.7460 mL | |
| 5 mM | 0.5149 mL | 2.5746 mL | 5.1492 mL | |
| 10 mM | 0.2575 mL | 1.2873 mL | 2.5746 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
